BenevolentAI Investor Day Presentation Deck
Ulcerative Colitis (UC)
Affects 0.4% US population (¹), 1.7 million
patients in 7MM(¹), forecast $7.8bn market by
2026(²)
• A chronic, lifelong disease that causes inflammation and
ulceration of the inner lining of the colon and rectum
• Efficacy - 20-40% of Moderate-severe patients do not respond to
anti-TNF (main treatment paradigm) (3)
• Safety - Treatments have many side effects from steroids to
anti-TNF and JAK inhibitors (black box warnings)(4)
• High unmet need for an alternative oral small molecule
treatment option with improved safety profile and efficacy in
treatment of refractory patients
64%
Mild-
moderate
Ulcerative Colitis
31%
Moderate-
severe
5%
Severe-
fulminant
Sources: (1) GlobalData: Ulcerative Colitis, Global Drug Forecast and Market Analysis to 2026; (2) Evaluate Pharma: Gastro-intestinal,
Inflammatory bowel disease (IBD), Ulcerative colitis, Worldwide Overview (report 17th Sep 2021); (3) Roda et al. Clin Transl Gastroenterol 2016;
(4) Kobayashi et al Nat Rev Dis Primers 2020 and US FDA Drug Safety Communication 2021
Experimental Model System: Inflamed
colonic mucosa biopsies from UC patients
• Disease phenotype retained with high basal cytokine release
• Readouts: IL6 and IL8 - key mediators of UC pathology
• Efficacy demonstrated with standard of care therapies
Culture 24 hrs
Cytokines in sups
Store biopsies
Single cell work
Western blots
PCR
Biopsies
NO:
SEX: AGE:
D.O.BIRTH:
SCU-47
NAME:
Resections
Lamina propria mononuclear
cells for in vitro activation
• Short term organ culture of human intestinal mucosa
. Gut is a tissue that is sampled a lot
• Inflamed biopsies do not know that they are not in the gut
Benevolent 52View entire presentation